Bottom line
Is PSIL a good fund? The bottom line
PSIL is an actively managed large blend ETF from Advisorshares.
Its expense ratio is 1% — about $100 a year on every $10,000 invested, more expensive than 64% of large blend funds we track.
It returned +73.4% over one year (as of Dec 31, 2025, per its prospectus).
With $44.4 million in net assets and 32 holdings, its largest position is Definium Therapeutics Inc (12.9%) and the top 10 make up 69.2% of the portfolio.
What to watch
- Concentrated: top 10 holdings are 69.2% of assets
- Small fund ($44.4 million) — small funds are likelier to close
Updated Nov 19, 2026
What PSIL invests in
The AdvisorShares Psychedelics ETF (the Fund) seeks long-term capital appreciation.
The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by primarily investing in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid-, small- and micro-capitalization companies. The Fund also may invest in total return swaps intended to provide exposure to such companies. Under normal circumstances, Fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. Psychedelic drugs, also known…
From the fund's prospectus (filed Oct 28, 2026).
PSIL performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PSIL | +73.4% | — | — |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What PSIL costs
On a $10,000 investment, PSIL's 1% expense ratio costs about $100 a year. The prospectus estimates $1,521 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
PSIL top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Definium Therapeutics Inc DFTX | 12.85% |
| 2 | Compass Pathways Plc CMPS | 11.45% |
| 3 | Ataibeckley Inc ATAI | 10.47% |
| 4 | Relmada Therapeutics Inc RLMD | 6.84% |
| 5 | Nrx Pharmaceuticals Inc NRXP | 6.07% |
| 6 | Neurocrine Biosciences Inc NBIX | 4.38% |
| 7 | Cybin Inc HELP | 4.35% |
| 8 | Gh Research Plc GHRS | 4.31% |
| 9 | Alkermes Plc ALKS | 4.30% |
| 10 | Alto Neuroscience Inc ANRO | 4.20% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 69.2% of the fund. See all top 25 holdings and asset mix →